JCML clinical trials at UCSF

1 research study open to eligible people

Juvenile myelomonocytic leukemia (JMML) is a rare cancer of blood cells in children. UCSF is testing trametinib plus azacitidine for people newly diagnosed with JMML. UCSF is collecting data on side effects and treatment response.

Showing trials for

  • Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    open to eligible people ages 1 month to 21 years

    This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

    San Francisco, California and other locations

Last updated: